GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perseus Proteomics Inc (TSE:4882) » Definitions » Capex-to-Revenue

Perseus Proteomics (TSE:4882) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Perseus Proteomics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Perseus Proteomics's Capital Expenditure for the three months ended in Dec. 2023 was 円0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was 円20.75 Mil.

Hence, Perseus Proteomics's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.00.


Perseus Proteomics Capex-to-Revenue Historical Data

The historical data trend for Perseus Proteomics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perseus Proteomics Capex-to-Revenue Chart

Perseus Proteomics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Revenue
Get a 7-Day Free Trial 0.05 0.03 0.04 0.47 1.81

Perseus Proteomics Quarterly Data
Mar18 Mar19 Dec19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Perseus Proteomics's Capex-to-Revenue

For the Drug Manufacturers - General subindustry, Perseus Proteomics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perseus Proteomics's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Perseus Proteomics's Capex-to-Revenue falls into.



Perseus Proteomics Capex-to-Revenue Calculation

Perseus Proteomics's Capex-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-170.548) / 94.201
=1.81

Perseus Proteomics's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 20.748
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perseus Proteomics  (TSE:4882) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Perseus Proteomics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Perseus Proteomics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Perseus Proteomics (TSE:4882) Business Description

Traded in Other Exchanges
N/A
Address
4-7-6, Komaba, Tokyo Park Building, Meguro-ku, Tokyo, JPN, 153-0041
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody based therapeutics and diagnostics drugs to cure against cancer and other diseases.

Perseus Proteomics (TSE:4882) Headlines

No Headlines